Skip to main content

Dyne Therapeutics, Inc.

DYN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001818794

In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.

Superinvestors holding DYN, Q2 2026

See all superinvestors

No superinvestor reported holding DYN in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of DYN each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q2 2023

    0 superinvestors holding at quarter end

    Sold out
    HHLR Advisors (Hillhouse)
  2. Q1 2023

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−49.1%)
  3. Q4 2022

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−6.0%)